Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2

References

• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257.
   PubMed Web of Science ®Google Scholar
• Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010;10:505–514.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.
   PubMed Web of Science ®Google Scholar
• Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611–625.
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–371.
   PubMed Web of Science ®Google Scholar
• Lamalice L, Boeuf FL, Huot J. Endothelial cell migration during angiogenesis. Circ Res. 2007;100:782–794.
   PubMed Web of Science ®Google Scholar
• Iyer S, Darley PI, Acharya KR. Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1D2 recognition and specifity. J Biol Chem. 2010;285:23779–23789.
   PubMed Web of Science ®Google Scholar
• Ning Q, Liu C, Hou L, et al. Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transition. PLoS One. 2013;8:e65217.
   PubMed Web of Science ®Google Scholar
• Li T, Zhu Y, Han L, et al. VEGFR-1 activation-induced MMP-9-dependent invasion in hepatocellular carcinoma. Future Oncol. 2015;11:3143–3157.
   PubMed Web of Science ®Google Scholar
• Micalizzi DS, Ford HL. Epithelial-mesenchymal transition in development and cancer. Future Oncol. 2009;5:1129–1143.
   PubMed Web of Science ®Google Scholar
• Bates RC, Goldsmith JD, Bachelder RE, et al. Flt-1-dependent survival characterizes the epithelial–mesenchymal transition of colonic organoids. Curr Biol. 2003;13:1721–1727.
   PubMed Web of Science ®Google Scholar
• Silva SR, Bowen KA, Rychahou PG, et al. VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis. Int J Cancer. 2011;128:1045–1056.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the ‘seed and soil’ theory of metastatic dissemination. Clin Exp Med. 2006;6:145–149.
   PubMed Web of Science ®Google Scholar
• Zijl FV, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res. 2011;728:23–34.
   PubMed Web of Science ®Google Scholar
• Stuelten CH, Parent CA, Montell DJ. Cell motility in cancer invasion and metastasis: insights from simple model organisms. Nat Rev Cancer. 2018;18:296–312.
   PubMed Web of Science ®Google Scholar
• Cowling VH, Cole MD. E-cadherin repression contributes to c-Myc-induced epithelial cell transformation. Oncogene. 2007;26:3582–3586.
   PubMed Web of Science ®Google Scholar
• Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer. 2009;125:2863–2870.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 2015;9:317–324.
   PubMed Web of Science ®Google Scholar
• Sadremomtaz A, Mansouri K, Alemzadeh G, et al. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway. Biochim Biophys Acta Gen Subj. 2018;1862:2688–2700.
   PubMed Web of Science ®Google Scholar
• Farzaneh Behelgardi M, Zahri S, Mashayekhi F. A peptide mimicking the binding sites of VEGF-A and VEGF-B inhibits VEGFR-1/-2 deriven angiogenesis, tumor growth and metastasis. Sci Rep. 2018;8:17924–17937.
   PubMed Web of Science ®Google Scholar
• Chamani R, Asghari SM, Alizadeh AM, et al. The antiangiogenic and antitumor activities of the N-terminal fragment of endostatin augmented by Ile/Arg substitution: the overall structure implicated the biological activity. Biochim Biophys Acta. 2016;1864:1765–1774.
   PubMed Web of Science ®Google Scholar
• Chamani R, Asghari SM, Alizadeh AM, et al. Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: mechanistic and therapeutic insights. Vascul Pharmacol. 2015;72:73–82.
   PubMed Web of Science ®Google Scholar
• Castaño Z, Marsh T, Tadipatri R, et al. Stromal EGF and IGF-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov. 2013;8:923–935.
   Google Scholar
• Lo HM, Shieh JM, Chen CL, et al. Vascular endothelial growth factor induces CXCL1 chemokine release via JNK and PI-3K-dependent pathways in human lung carcinoma epithelial cells. Int J Mol Sci. 2013;14:10090–10106.
   PubMed Web of Science ®Google Scholar
• Kazazian K, Go C, Wu H, et al. Plk4 promotes cancer invasion and metastasis through Arp2/3 complex regulation of the actin cytoskeleton. Cancer Res. 2017;77:434–447.
   PubMed Web of Science ®Google Scholar
• Likhite N, Warawdekar UM. A unique method for isolation and solubilization of proteins after extraction of RNA from tumor tissue using Trizol. J Biomol Tech. 2011;22:37–44.
   PubMedGoogle Scholar
• Zygalaki E, Tsaroucha EG, Kaklamanis L, et al. Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non- small cell lung cancer. Clin Chem. 2007;53:1433–1439.
   PubMed Web of Science ®Google Scholar
• Shi C, Liu D, Xiao Z, et al. Monitoring tumor response to antivascular therapy using non-contrast intravoxel incoherent motion diffusion-weighted MRI. Cancer Res. 2017;77:3491–3501.
   PubMed Web of Science ®Google Scholar
• De Rosa L, Finetti F, Diana D, et al. Miniaturizing VEGF: peptides mimicking the discontinuous VEGF receptor-binding site modulate the angiogenic response. Sci Rep. 2016;6:31295.
   PubMed Web of Science ®Google Scholar
• Vicari D, Foy KC, Liotta EM, et al. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem. 2011;286:13612–13625.
   PubMed Web of Science ®Google Scholar
• Brozzo MS, Bjelic S, Kisko K, et al. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood. 2012;119:1781–1788.
   PubMed Web of Science ®Google Scholar
• Han SW, Jung YK, Lee EJ, et al. DICAM inhibits angiogenesis via suppression of AKT and p38 MAP kinase signalling. Cardiovasc Res. 2013;98:73–82.
   PubMed Web of Science ®Google Scholar
• Saraswati S, Kumar S, Alhaider AA. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol Cancer. 2013;12:147–165.
   PubMed Web of Science ®Google Scholar
• Kwak HJ, Park MJ, Park CM, et al. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer. 2006;118:2711–2720.
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–196.
   PubMed Web of Science ®Google Scholar
• Cudmore MJ, Hewett PW, Ahmad S, et al. The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat Commun. 2012;3:972.
   PubMed Web of Science ®Google Scholar
• Yu D, Lee J, Yoo J, et al. Soluble vascular endothelial growth factor decoy receptor FP3 experts potent antiangiogenic effects. Mol Ther. 2012;20:938–947.
   PubMed Web of Science ®Google Scholar
• Don F, Zhou X, Li C. Dihydroartemisinin targets VEGFR2 via the NF-kB pathway in endothelial cells to inhibit angiogenesis. Cancer Biol Ther. 2014;15:1479–1488.
   PubMed Web of Science ®Google Scholar
• Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5:402–418.
   PubMed Web of Science ®Google Scholar
• Kong DH, Kim MR, Jang JH, et al. A review of anti-angiogenic targets for monoclonal antibody cancer therapy. Int J Mol Sci. 2017;18:pii: E1786.
   Web of Science ®Google Scholar
• Lawson C, Schlaepfer DD. Integrin adhesions: who’s on first? What’s on second? Connections between FAK and talin. Cell Adh Migr. 2012;6:302–306.
   PubMed Web of Science ®Google Scholar
• Canel M, Serrels A, Frame MC, et al. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci. 2013;126:393–401.
   PubMed Web of Science ®Google Scholar
• Huang D, Khoe M, Befekadu M, et al. Focal adhesion kinase mediates cell survival via NF-B and ERK signaling pathways. Am J Physiol Cell Physiol. 2007;292:C1339–C1352.
   PubMed Web of Science ®Google Scholar
• Liu ZX, Yu CF, Nickel C, et al. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. J Biol Chem. 2002;277:10452–10458.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Pan Y, Cheng Y, et al. Lunasin suppresses the migration and invasion of breast cancer cells by inhibiting matrix metalloproteinase-2/-9 via the FAK/Akt/ERK and NF-κB signaling pathways. Oncol Rep. 2016;36:253–262.
   PubMed Web of Science ®Google Scholar
• Min KW, Kim DH, Do SI, et al. Expression patterns of stromal MMP-2 and tumoural MMP-2 and -9 are significant prognostic factors in invasive ductal carcinoma of the breast. APMIS. 2014;122:1196–1206.
   PubMed Web of Science ®Google Scholar